Leber Werner, Panovska-Griffiths Jasmina, Martin Peter, Morris Stephen, Capelas Barbosa Estela, Estcourt Claudia, Hutchinson Jane, Shahmanesh Maryam, El-Shogri Farah, Boomla Kambiz, Delpech Valerie, Creighton Sarah, Anderson Jane, Figueroa Jose, Griffiths Chris
Institute of Population Health Sciences, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London United Kingdom.
Department of Applied Health Research, University College London, London, United Kingdom.
EClinicalMedicine. 2020 Jan 10;19:100229. doi: 10.1016/j.eclinm.2019.11.022. eCollection 2020 Feb.
UK and European guidelines recommend HIV testing in general practice. We report on the implementation of the Rapid HIV Assessment trial (RHIVA2) promoting HIV screening in general practice into routine care.
Interrupted time-series, difference-in-difference analysis and Pearson-correlation on three cohorts comprising 42 general practices in City & Hackney (London, UK); covering three periods: pre-trial (2009-2010), trial (2010-2012) and implementation (2012-2014). Cohorts comprised practices receiving: "trial intervention" only ( = 19), "implementation intervention" only ( = 13); and neither ("comparator") ( = 10). Primary outcomes were HIV testing and diagnosis rates per 1000 people and CD4 at diagnosis.
Overall, 55,443 people were tested (including 38,326 among these cohorts), and 101 people were newly diagnosed HIV positive (including 65 among these cohorts) including 74 (73%) heterosexuals and 69 (68%) people of black African/Caribbean background; with mean CD4 count at diagnosis 357 (SD=237). Among implementation intervention practices, testing rate increased by 85% (from 1·798 (95%CI=(1·657,1·938) at baseline to 3·081 (95%CI=(2·865,3·306); = 0·0000), diagnosis rate increased by 34% (from 0·0026 (95%CI=(0·0004,0·0037)) to 0·0035 (95%CI=(0·0007,0·0062); = 0·736), and mean CD4 count at diagnosis increased by 55% (from 273 (SD=372) to 425 (SD=274) cells per μL; = 0·433). Implementation intervention and trial intervention practices achieved similar testing rates (3·764 vs. 3·081; 6% difference; 95% CI=(-5%,18%); = 0·358), diagnosis rates (0·0035 vs. 0·0081; -13% difference; 95%CI=(-77%,244%; = 0·837), and mean CD4 count (425 (SD=274) vs. 351 (SD=257); 69% increase; 95% CI=(-61%,249%); = 0·359). HIV testing was positively correlated with diagnosis ( = 0·114 (95% CI=[0·074,0·163])), and diagnosis with CD4 count at diagnosis ( = 0·011 (95% CI=[-0·177,0·218])).
Implementation of the RHIVA programme promoting nurse-led HIV screening into routine practice in inner-city practices with high HIV prevalence increased HIV testing, and may be associated with increased and earlier diagnosis. HIV screening in primary care should be considered a key strategy to reduce undiagnosed infection particularly among high risk persons not attending sexual health services.
National Institute for Health Research ARC North Thames, and Barts and The London School of Medicine and Dentistry.
英国和欧洲的指南建议在全科医疗中进行HIV检测。我们报告了促进HIV筛查在全科医疗中纳入常规护理的快速HIV评估试验(RHIVA2)的实施情况。
对英国伦敦市和哈克尼的42家全科诊所的三个队列进行中断时间序列分析、差异分析和Pearson相关性分析;涵盖三个时期:试验前(2009 - 2010年)、试验期(2010 - 2012年)和实施期(2012 - 2014年)。队列包括仅接受“试验干预”的诊所((n = 19))、仅接受“实施干预”的诊所((n = 13))以及两者都不接受的诊所(“对照”)((n = 10))。主要结局是每1000人的HIV检测率和诊断率以及诊断时的CD4水平。
总体而言,共检测了55443人(包括这些队列中的38326人),101人新诊断为HIV阳性(包括这些队列中的65人),其中74人(73%)为异性恋者,69人(68%)为非洲/加勒比黑人背景;诊断时的平均CD4计数为357(标准差 = 237)。在实施干预的诊所中,检测率提高了85%(从基线时的1.798(95%置信区间 =(1.657,1.938))提高到3.081(95%置信区间 =(2.865,3.306);(P = 0.0000)),诊断率提高了34%(从0.0026(95%置信区间 =(0.0004,0.0037))提高到0.0035(95%置信区间 =(0.0007,0.0062);(P = 0.736)),诊断时的平均CD4计数提高了55%(从每微升273(标准差 = 372)提高到425(标准差 = 274)个细胞;(P = 0.433))。实施干预和试验干预的诊所的检测率相似(3.764对3.081;差异为6%;95%置信区间 =(-5%,18%);(P = 0.358)),诊断率相似(0.0035对0.0081;差异为 - 13%;95%置信区间 =(-77%,244%;(P = 0.837)),平均CD4计数相似(425(标准差 = 274)对351(标准差 = 257);增加69%;95%置信区间 =(-61%,249%);(P = 0.359))。HIV检测与诊断呈正相关((r = 0.114)(95%置信区间 = [0.074,0.163])),诊断与诊断时的CD4计数呈正相关((r = 0.011)(95%置信区间 = [-0.177,0.218]))。
在HIV感染率高的市中心诊所实施由护士主导的HIV筛查的RHIVA计划,提高了HIV检测率,可能与增加诊断和早期诊断有关。初级保健中的HIV筛查应被视为减少未诊断感染的关键策略,特别是在未就诊于性健康服务机构的高危人群中。
国家卫生研究院北泰晤士地区研究协作中心,以及巴茨和伦敦医学与牙科学院。